Future perspectives for mTOR inhibitors in renal cell cancer treatment

Papers of special note have been highlighted as: •• of considerable interest

References

• 1 Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A Phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115(11), 2438–2446 (2009).
  Medline CASGoogle Scholar
• 2 Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol. Cancer Ther. 7(6), 1347–1354 (2008).
  Medline CASGoogle Scholar
• 3 Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18(16), 1926–1945 (2004).
  Medline CASGoogle Scholar
• 4 Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 12(1), 9–22 (2007).
  Medline CASGoogle Scholar
• 5 Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5(8), 671–688 (2006).
  Medline CASGoogle Scholar
• 6 Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin. Cancer Res. 12(24), 7215–7220 (2006).
  Medline CASGoogle Scholar
• 7 Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80(7), 883–889 (2005).
  Medline CASGoogle Scholar
• 8 Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a Phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26(10), 1603–1610 (2008).
  Medline CASGoogle Scholar
• 9 Stein A, Wang W, Carter AA et al. Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the Phase 3 RECORD-1 trial. BMC Cancer 12, 311 (2012).
  Medline CASGoogle Scholar
• 10 Anandappa G, Hollingdale A, Eisen T. Everolimus - a new approach in the treatment of renal cell carcinoma. Cancer Manag. Res. 2, 61–70 (2010).
  Medline CASGoogle Scholar
• 11 Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449–456 (2008).
  Medline CASGoogle Scholar
• 12 Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18), 4256–4265 (2010).
  Medline CASGoogle Scholar
• 13 Calvo E, Escudier B, Motzer RJ et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the Phase III RECORD-1 study. Eur. J. Cancer 48(3), 333–339 (2012).•• This is the first and only Phase III – RECORD-1 – trial demonstrated clinical benefit of everolimus over placebo in treatment-resistant patients with metastatic RCC. It was underlined that the Response Evaluation Criteria in Solid Tumors (RECIST) objective response rate was low. The study shows that the benefit and the safety of the drug are independent of the age of patients. Moreover, regardless of response on prior TKI therapy, the percentage of patients with stable disease who received everolimus was about two-times higher than those who received placebo.
  Medline CASGoogle Scholar
• 14 Oudard S, Thiam R, Fournier LS et al. Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. Eur. J. Cancer 48(10), 1512–1518 (2012).
  Medline CASGoogle Scholar
• 15 Bracarda S, Hutson TE, Porta C et al. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. Br. J. Cancer 106(9), 1475–1480 (2012).
  Medline CASGoogle Scholar
• 16 Grunwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br. J. Cancer 105(11), 1635–1639 (2011).
  Medline CASGoogle Scholar
• 17 Di Lorenzo G, Buonerba C, Federico P et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur. Urol. 58(6), 906–911 (2010).
  Medline CASGoogle Scholar
• 18 Heng DY, Mackenzie MJ, Vaishampayan UN et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann. Oncol. 23(6), 1549–1555 (2012).
  Medline CASGoogle Scholar
• 19 Porta C, Calvo E, Climent MA et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur. Urol. 61(4), 826–833 (2012).
  Medline CASGoogle Scholar
• 20 White DA, Camus P, Endo M et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J. Respir. Crit. Care Med. 182(3), 396–403 (2010).
  MedlineGoogle Scholar
• 21 Beaumont JL, Butt Z, Baladi J et al. Patient-reported outcomes in a Phase III study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. Oncologist 16(5), 632–640 (2011).
  Medline CASGoogle Scholar
• 22 Grunwald V, Karakiewicz PI, Bavbek SE et al. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur. J. Cancer 48(3), 324–332 (2012).
  MedlineGoogle Scholar
• 23 Van Den Eertwegh AJ, Karakiewicz P, Bavbek S et al. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. Urology 81(1), 143–149 (2013).
  MedlineGoogle Scholar
• 24 Bergmann L, Goebell PJ, Kube U et al. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study. Onkologie 36(3), 95–100 (2013).
  Medline CASGoogle Scholar
• 25 Czarnecka A, Sobczuk P, Bogusz K, Spychalska M, Szczylik C. Survival, safety and treatment response duration in “real world” patients with metastatic clear cell renal cancer – an update from clinical practice. BJU International 112(s3), 1–17 (2013).
  Google Scholar
• 26 Poprach A, Bortlicek Z, Buchler T et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Med Oncol. 29(5), 3314–3320 (2012).
  MedlineGoogle Scholar
• 27 Tsukamoto T, Shinohara N, Tsuchiya N et al. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn. J. Clin. Oncol. 41(1), 17–24 (2011).
  MedlineGoogle Scholar
• 28 Maraz A, Bodoky G, Dank M et al. Experience with everolimus therapy for patients with metastatic renal cancer in Hungary. Magy Onkol 58(1), 4–9 (2014).
  MedlineGoogle Scholar
• 29 Guo J, Huang Y, Zhang X et al. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label Phase 1b study. BMC Cancer 13, 136 (2013).
  Medline CASGoogle Scholar
• 30 Koh Y, Lim HY, Ahn JH et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann. Oncol. 24(4), 1026–1031 (2013).
  Medline CASGoogle Scholar
• 31 Escudier BJ, Bracarda S, Maroto JP et al. Open-label Phase II trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Ann. Oncol. 23(9), 264 (2013).•• The first Phase II study to investigate the use of everolimus for the initial treatment of advanced papillary kidney cancer. It has shown that everolimus is successful in slowing or preventing the spread of the disease. This study is unique as it was the first study of an mTOR inhibitor to enroll patients only with advanced papillary RCC and diagnosis was also confirmed by an independent group of pathologists experienced in the classification of RCC to prevent any patients being enrolled incorrectly.
  Google Scholar
• 32 Vrdoljak E, Ciuleanu T, Kharkevich G et al. Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region. Expert Opin. Pharmacother. 13(2), 159–174 (2012).
  Medline CASGoogle Scholar
• 33 Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit. Rev. Oncol. Hematol. 82(3), 323–337 (2012).•• In this manuscript, few questions about the optimal sequence of RCC treatment have been answered. Both everolimus and axitinib have been suggested as standard of care after failure of first-line TKI treatment. Sorafenib has been proposed as an additional option in such clinical situation. It was shown that in clinical practice, several factors may influence the choice of subsequent treatment. Considerations on appropriate drug exposure in first-line, gained insights on prognostic and predictive factors as well as mechanisms of resistance are shown. The decision schema of second-line therapy has been shown and challenges of what to offer in third- and later lines are suggested.
  MedlineGoogle Scholar
• 34 Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat. Rev. 36(1), 16–23 (2012).
  Google Scholar
• 35 Buczek M, Escudier B, Bartnik E, Szczylik C, Czarnecka A. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. Biochim. Biophys. Acta 1845(1), 31–41 (2014).
  Medline CASGoogle Scholar
• 36 Vickers MM, Choueiri TK, Rogers M et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 76(2), 430–434 (2010).
  MedlineGoogle Scholar
• 37 Busch J, Seidel C, Kempkensteffen C et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur. Urol. 60(6), 1163–1170 (2011).
  MedlineGoogle Scholar
• 38 Signorovitch JE, Vogelzang NJ, Pal SK et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr. Med. Res. Opin. 30(11), 2343–2353 (2014).
  Medline CASGoogle Scholar
• 39 Iacovelli R, Santoni M, Verzoni E et al. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clin. Genitourin. Cancer 8(3-4), E121–E125 (2014).
  Google Scholar
• 40 Motzer RJ, Barrios CH, Kim TM et al. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 31(Suppl.), Abstract 4504 (2013).
  MedlineGoogle Scholar
• 41 Blesius A, Beuselinck B, Chevreau C et al. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. Clin. Genitourin. Cancer 11(2), 128–133 (2013).
  MedlineGoogle Scholar
• 42 Maj-Hes A, Medioni J, Scotte F et al. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy. Oncology 85(1), 8–13 (2013).
  Medline CASGoogle Scholar
• 43 Maj-Hes A, Elaidi R-T, Medioni J et al. What is the benfit of mTOR inhibitors (mTORi) rechallenge in metastatic renal clear cell carcinoma (mRCC) patients (pts) initially treated with TKI. J. Clin. Oncol. 30(Suppl. 5), Abstract 442 (2012).
  Google Scholar
• 44 Goebell PJ, Kube U, Staehler MD et al. Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: final results of the noninterventional change study. J. Clin. Oncol. 32(Suppl. 4), Abstract 469 (2014).
  Google Scholar
• 45 Sun M, Shariat SF, Trinh QD et al. An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. Ther. Adv. Urol. 5(2), 121–128 (2013).
  Medline CASGoogle Scholar
• 46 Ryan CW, Vuky J, Chan JS, Chen Z, Beer TM, Nauman D. A Phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. Invest. New Drugs 29(2), 374–379 (2011).
  Medline CASGoogle Scholar
• 47 Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J. Clin. Oncol. 28(13), 2131–2136 (2010).
  Medline CASGoogle Scholar
• 48 Harshman LC, Barbeau S, Mcmillian A, Srinivas S. A Phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Clin. Genitourin. Cancer 11(2), 100–106 (2013).
  MedlineGoogle Scholar
• 49 Harzstark AL, Small EJ, Weinberg VK et al. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 117(18), 4194–4200 (2011).
  Medline CASGoogle Scholar
• 50 Amato RJ, Flaherty AL, Stepankiw M. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. Clin. Genitourin. Cancer 10(1), 26–31 (2012).
  MedlineGoogle Scholar
• 51 Hainsworth JD, Waterhouse DM, Penley WC et al. Sorafenib and everolimus in advanced clear cell renal carcinoma: a Phase I/II trial of the SCRI Oncology Research Consortium. Cancer Invest. 31(5), 323–329 (2013).
  Medline CASGoogle Scholar
• 52 Molina AM, Feldman DR, Voss MH et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118(7), 1868–1876 (2012).
  Medline CASGoogle Scholar
• 53 Powles T, Foreshew SJ, Shamash J et al. A Phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. Eur. J. Cancer 50(12), 2057–2064 (2014).
  Medline CASGoogle Scholar
• 54 Molina AM, Hutson TE, Larkin J et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother. Pharmacol. 73(1), 181–189 (2014).
  Medline CASGoogle Scholar
• 55 Feala JD, Cortes J, Duxbury PM, Piermarocchi C, Mcculloch AD, Paternostro G. Systems approaches and algorithms for discovery of combinatorial therapies. Wiley Interdiscip. Rev. Syst. Biol. Med. 2(2), 181–193 (2010).
  MedlineGoogle Scholar
• 56 Calderwood SK. Tumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapy. Discov. Med. 15(82), 188–194 (2013).
  MedlineGoogle Scholar
• 57 Lehar J, Zimmermann GR, Krueger AS et al. Chemical combination effects predict connectivity in biological systems. Mol. Syst. Biol. 3, 80 (2007).
  MedlineGoogle Scholar
• 58 Nelander S, Wang W, Nilsson B et al. Models from experiments: combinatorial drug perturbations of cancer cells. Mol. Syst. Biol. 4, 216 (2008).
  MedlineGoogle Scholar
• 59 Liu YN, Wan RZ, Liu ZP. Recent developments of small molecule PI3K/mTOR dual inhibitors. Mini. Rev. Med. Chem. 13(14), 2047–2059 (2013).
  Medline CASGoogle Scholar
• 60 Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10(3), 143–153 (2013).
  Medline CASGoogle Scholar
• 61 Gedaly R, Galuppo R, Musgrave Y et al. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. J. Surg. Res. 185(1), 225–230 (2013).
  Medline CASGoogle Scholar
• 62 Zhang H, Berel D, Wang Y et al. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS ONE 8(1), e54918 (2013).
  Medline CASGoogle Scholar
• 63 Bussolati B, Brossa A, Camussi G. Resident stem cells and renal carcinoma. Int. J. Nephrol. 2011, 286985 (2011).
  MedlineGoogle Scholar
• 64 Zhang Y, Sun B, Zhao X et al. Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma. J. Surg. Oncol. 108(6), 414–419 (2013).
  Medline CASGoogle Scholar
• 65 Sehl ME, Sinsheimer JS, Zhou H, Lange KL. Differential destruction of stem cells: implications for targeted cancer stem cell therapy. Cancer Res. 69(24), 9481–9489 (2009).
  Medline CASGoogle Scholar
• 66 Smith KM, Datti A, Fujitani M et al. Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol. Med. 2(9), 371–384 (2010).
  Medline CASGoogle Scholar
• 67 Azzi S, Bruno S, Giron-Michel J et al. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J. Natl Cancer Inst. 103(24), 1884–1898 (2011).
  Medline CASGoogle Scholar
• 68 Thoreen CC, Kang SA, Chang JW et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284(12), 8023–8032 (2009).
  Medline CASGoogle Scholar
• 69 Wang K, Li Z, Chen Y, Su C. The pharmacokinetics of a novel anti-tumor agent, beta-elemene, in Sprague-Dawley rats. Biopharm. Drug Dispos. 26(7), 301–307 (2005).
  Medline CASGoogle Scholar
• 70 Zhan YH, Liu J, Qu XJ et al. Beta-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/mTOR signalling pathways. Asian Pac. J. Cancer Prev. 13(6), 2739–2744 (2012).
  MedlineGoogle Scholar
• 71 Chen G, Zhang W, Li YP et al. Hypoxia-induced autophagy in endothelial cells: a double-edged sword in the progression of infantile haemangioma? Cardiovasc. Res. 98(3), 437–448 (2013).
  Medline CASGoogle Scholar
• 72 Csermely P, Korcsmaros T. Cancer-related networks: a help to understand, predict and change malignant transformation. Semin. Cancer Biol. 23(4), 209–212 (2013).
  Medline CASGoogle Scholar
• 73 Kubisch J, Turei D, Foldvari-Nagy L et al. Complex regulation of autophagy in cancer – integrated approaches to discover the networks that hold a double-edged sword. Semin. Cancer Biol. 23(4), 252–261 (2013).
  MedlineGoogle Scholar
• 74 Kim KW, Paul P, Qiao J, Chung DH. Autophagy mediates paracrine regulation of vascular endothelial cells. Lab. Invest. 93(6), 639–645 (2013).
  Medline CASGoogle Scholar
• 75 Heuser M, Schlott T, Schally AV et al. Expression of gastrin releasing Peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion. J. Urol. 173(6), 2154–2159 (2005).
  Medline CASGoogle Scholar
• 76 Kim KW, Paul P, Qiao J, Lee S, Chung DH. Enhanced autophagy blocks angiogenesis via degradation of gastrin-releasing peptide in neuroblastoma cells. Autophagy 9(10), 1579–1590 (2013).
  Medline CASGoogle Scholar
• 77 Liu Y, Zhang X, Liu J, Hou G, Zhang S, Zhang J. Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study. Tumour Biol. 35(2), 1275–1286 (2014).
  MedlineGoogle Scholar
• 78 Siejka A, Barabutis N, Schally AV. GHRH antagonist MZ-5–156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle 10(21), 3714–3718 (2011).
  Medline CASGoogle Scholar
• 79 Sustarsic EG, Junnila RK, Kopchick JJ. Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment. Biochem. Biophys. Res. Commun. 441(1), 144–150 (2013).
  Medline CASGoogle Scholar
• 80 Block M, Grundker C, Fister S et al. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. Int. J. Oncol. 41(5), 1845–1854 (2012).
  Medline CASGoogle Scholar
• 81 Brewer C, Yeager N, Di Cristofano A. Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res. 67(17), 8002–8006 (2007).
  Medline CASGoogle Scholar
• 82 Bishop JD, Nien WL, Dauphinee SM, Too CK. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells. J. Endocrinol. 190(2), 307–312 (2006).
  Medline CASGoogle Scholar
• 83 Rapley J, Oshiro N, Ortiz-Vega S, Avruch J. The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling. J. Biol. Chem. 286(44), 38043–38053 (2011).
  Medline CASGoogle Scholar
• 84 Kang JW, Cho HI, Lee SM. Melatonin inhibits mTOR-dependent autophagy during liver ischemia/reperfusion. Cell Physiol. BioChem. 33(1), 23–36 (2014).
  Medline CASGoogle Scholar
• 85 Guo X, Zhou CY, Li Q et al. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor. Biomed. Environ. Sci. 26(5), 371–381 (2013).
  Medline CASGoogle Scholar
• 86 Polman JA, Hunter RG, Speksnijder N et al. Glucocorticoids modulate the mTOR pathway in the hippocampus: differential effects depending on stress history. Endocrinology 153(9), 4317–4327 (2012).
  Medline CASGoogle Scholar
• 87 Hou X, Zhao M, Wang T, Zhang G. Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway. Oncol. Rep. 31(3), 1175–1182 (2014).
  Medline CASGoogle Scholar
• 88 Barone I, Cui Y, Herynk MH et al. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res. 69(11), 4724–4732 (2009).
  Medline CASGoogle Scholar
• 89 Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7(5), 277–285 (2010).
  Medline CASGoogle Scholar
• 90 Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc. Natl Acad. Sci. USA 97(19), 10555–10560 (2000).
  Medline CASGoogle Scholar
• 91 Schmidinger M, Vogl UM, Bojic M et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117(3), 534–544 (2011).
  MedlineGoogle Scholar
• 92 Cardillo TM, Trisal P, Arrojo R, Goldenberg DM, Chang CH. Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer 13, 170 (2013).
  Medline CASGoogle Scholar
• 93 Park EJ, Woo SM, Min KJ, Kwon TK. Transcriptional and post-translational regulation of Bim controls apoptosis in melatonin-treated human renal cancer Caki cells. J. Pineal Res. 56(1), 97–106 (2014).
  Medline CASGoogle Scholar
• 94 Yakirevich E, Matoso A, Sabo E et al. Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study. Hum. Pathol. 42(11), 1684–1692 (2011).
  Medline CASGoogle Scholar
• 95 Yu CP, Ho JY, Huang YT et al. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-beta activation. PLoS ONE 8(2), e56667 (2013).
  Medline CASGoogle Scholar
• 96 Gaiser T, Ruschoff J, Schally AV, Keller G, Engel JB. Receptors for luteinizing hormone releasing hormone expressed on melanoma, renal cell carcinoma and non Hodgkin lymphoma can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Verh. Dtsch Ges. Pathol. 90, 186–192 (2006).
  Medline CASGoogle Scholar
• 97 Malaguarnera R, Belfiore A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front. Endocrinol. (Lausanne) 5, 10 (2014).
  MedlineGoogle Scholar
• 98 Quek R, Wang Q, Morgan JA et al. Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin. Cancer Res. 17(4), 871–879 (2011).
  Medline CASGoogle Scholar
• 99 Guttilla IK, Adams BD, White BA. ERalpha, microRNAs, and the epithelial–mesenchymal transition in breast cancer. Trends Endocrinol. Metab. 23(2), 73–82 (2012).
  Medline CASGoogle Scholar
• 100 Janakiram NB, Mohammed A, Brewer M et al. Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. Cancer Prev. Res. (Phila) 7(3), 300–309 (2014).
  Medline CASGoogle Scholar
• 101 Jung YS, Lee SJ, Yoon MH, Ha NC, Park BJ. Estrogen receptor alpha is a novel target of the Von Hippel–Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions. Cell Cycle 11(23), 4462–4473 (2012).
  Medline CASGoogle Scholar
• 102 Neradugomma NK, Subramaniam D, Tawfik OW et al. Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner. Carcinogenesis 5(4), 795–806 (2013).
  Google Scholar
• 103 D'angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc. Natl Acad. Sci. USA 92(14), 6374–6378 (1995).
  MedlineGoogle Scholar
• 104 Martin V, Sanchez-Sanchez AM, Herrera F et al. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br. J. Cancer 108(10), 2005–2012 (2013).
  Medline CASGoogle Scholar
• 105 Kim KJ, Choi JS, Kang I, Kim KW, Jeong CH, Jeong JW. Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model. J. Pineal Res. 54(3), 264–270 (2013).
  Medline CASGoogle Scholar
• 106 Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat. Clin Pract Endocrinol. Metab 4(1), 33–43 (2008).
  Medline CASGoogle Scholar
• 107 Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr. Oncol. Rep. 11(2), 94–101 (2009).
  Medline CASGoogle Scholar
• 108 Koh MY, Darnay BG, Powis G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol. Cell Biol. 28(23), 7081–7095 (2008).
  Medline CASGoogle Scholar
• 109 Tabruyn SP, Sorlet CM, Rentier-Delrue F et al. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol. Endocrinol. 17(9), 1815–1823 (2003).
  Medline CASGoogle Scholar
• 110 Kinet V, Nguyen NQ, Sabatel C et al. Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer Lett. 284(2), 222–228 (2009).
  Medline CASGoogle Scholar
• 111 Surazynski A, Miltyk W, Wolczynski S, Palka J. The effect of prolactin and estrogen cross-talk on prolidase-dependent signaling in MCF-7 cells. Neoplasma 60(4), 355–363 (2013).
  Medline CASGoogle Scholar